Biopharmaceutical firm Eikon Therapeutics (EIKN.US) announced on Wednesday that its initial public offering in the United States has raised $381.2 million. The company issued approximately 21.2 million shares of common stock, priced at $18 per share. This pricing is at the upper end of the company's targeted range of $16 to $18 per share. The listing comes as the U.S. IPO market has shown signs of recovery in 2026. A government shutdown in October of last year had previously caused several companies to postpone their listing plans. Earlier this year, the biotech IPO sector also experienced a revival, with companies such as SpyGlass Pharma (SGP.US) and AgomAb Therapeutics (AGMB.US) filing for U.S. listings in January. Eikon Therapeutics was founded in 2019 by Nobel laureates in Chemistry Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian. The company is currently developing a pipeline of multiple experimental cancer therapies. Its most advanced drug candidate, EIK1001, is being evaluated in a mid-to-late-stage clinical trial for a type of skin cancer in combination with Merck's (MRK.US) Keytruda. Interim analysis data from this study is expected to be released in the second half of 2026. Shares of Eikon Therapeutics are scheduled to begin trading on the Nasdaq on Thursday under the ticker symbol "EIKN". The underwriters for the IPO include J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho Securities.